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Mechanisms Underlying the Scratching Behavior
Induced by the Activation of Proteinase-Activated
Receptor-4 in Mice
Eliziane S. Patricio1,7, Robson Costa1,2,7, Claudia P. Figueiredo1,2, Katharina Gers-Barlag3, Maíra A. Bicca1,
Marianne N. Manjavachi1, Gabriela C. Segat1, Clive Gentry3, Ana P. Luiz1, Elizabeth S. Fernandes4,5,
Thiago M. Cunha6, Stuart Bevan3 and João B. Calixto1,8
A role for proteinase-activated receptor-4 (PAR-4) was recently suggested in itch sensation. Here, we investigated
the mechanisms underlying the pruriceptive actions of the selective PAR-4 agonist AYPGKF-NH2 (AYP) in mice.
Dorsal intradermal (i.d.) administration of AYP elicited intense scratching behavior in mice, which was prevented
by the selective PAR-4 antagonist (pepducin P4pal-10). PAR-4 was found to be coexpressed in 32% of tryptase-
positive skin mast cells, and AYP caused a 2-fold increase in mast cell degranulation. However, neither the
treatment with cromolyn nor the deﬁciency of mast cells (WBB6F1-KitW/Wv mice) was able to affect AYP-induced
itch. PAR-4 was also found on gastrin-releasing peptide (GRP)-positive neurons (pruriceptive ﬁbers), and AYP-
induced itch was reduced by the selective GRP receptor antagonist RC-3095. In addition, AYP evoked calcium
inﬂux in ∼ 1.5% of cultured DRG neurons also sensitive to TRPV1 (capsaicin) and/or TRPA1 (AITC) agonists.
Importantly, AYP-induced itch was reduced by treatment with either the selective TRPV1 (SB366791), TRPA1
(HC-030031), or NK1 (FK888) receptor antagonists. However, genetic loss of TRPV1, but not of TRPA1, diminished
AYP-induced calcium inﬂux in DRG neurons and the scratching behavior in mice. These ﬁndings provide
evidence that PAR-4 activation by AYP causes pruriceptive itch in mice via a TRPV1/TRPA1-dependent mechanism.
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INTRODUCTION
Itch is a common symptom of dermatological and systemic
diseases such as atopic dermatitis and cholestasis (Ikoma
et al., 2006). Chronic itching remains without satisfactory
treatment and lowers patients’ quality of life (Weisshaar et al.,
2006). Studies using pruritogenic spicules obtained from
cowhage (Mucuna pruriens) have revealed the existence of
pruriceptive afferents distinct from the well-known histami-
nergic pathway (Davidson et al., 2007; Johanek et al., 2007;
Namer et al., 2008). The active component of cowhage
is mucunain, a cysteine protease that acts as an activator
of protease-activated receptors (PARs) (Shelley and Arthur,
1955; Reddy et al., 2008). PARs are a subfamily of G-protein-
coupled receptors, named PAR-1 to 4, that are activated by
the proteolytic cleavage of their extracellular domain
(Vergnolle, 2009).
With the discovery of PAR-2 involvement in itch, great
progress has been made in terms of understanding the
pathophysiological basis of itching (Steinhoff et al., 2003).
PAR-2 (Costa et al., 2008, 2010) and, more recently, PAR-4
(Kempkes et al., 2014) were suggested to mediate itch. PAR-4
is expressed on rodent sensory neurons (Asfaha et al., 2007;
Auge et al., 2009) and can be activated by several endo-
genous proteinases and synthetic hexapeptides (Fu et al.,
2014). Interestingly, the itch-causing agent mucunain cleaves
PAR-4 more potently than PAR-2 (Reddy et al., 2008).
Furthermore, it was shown that cathepsin S, an endogenous
cysteine protease that shares sequence homology with the
mucunain active site, evokes itch in humans via activation
of both PAR-2 and PAR-4 (Reddy et al., 2010). Indeed,
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intradermal (i.d.) injection of PAR-4 agonists caused scratch-
ing behavior in mice (Tsujii et al., 2008; Akiyama et al., 2009,
2010).
Although evidences suggest a role for PAR-4 in itch, the
signaling mechanisms involved in this process are poorly
understood. Here we investigated the cellular and molecular
mechanisms associated with the scratching behavior induced
by the PAR-4-activating peptide AYPGKF-NH2 (AYP) in mice,
and provided data supporting the role of PAR-4 in itch. We
show that AYP elicits scratching behavior in mice by
activating transient receptor potential (TRP) channels and
possibly causing the release of itch-mediating neurotransmit-
ters. These ﬁndings highlight the potential of PAR-4 as a target
for the development of antipruritic drugs.
RESULTS
PAR-4 activation induces scratching behavior in mice
I.d. administration of the selective PAR-4 agonist AYP, but not
the inactive peptide YAPGKF-NH2 (YAP), elicited scratching
behavior when injected into the back of the mouse neck
(Figure 1a) with an effective dose ranging from 100 to 500
nmol per site and an estimated mean ED50 value (accom-
panied by 95% conﬁdence limit) of 156 (42–572) nmol per
site. The dose of 200 nmol per site was chosen for all the
subsequent experiments. AYP-induced scratching behavior
was time-dependent, peaking within 10minutes and
decreasing slowly over time, without a signiﬁcant response
at 30minutes (Figure 1b). Interestingly, the number and the
time-course proﬁles of AYP-evoked scratching bouts were
similar to those caused by histamine (Figures 1a and b), a
widely known pruritogenic agent. As expected, pretreatment
with the selective PAR-4 antagonist pepducin P4pal-10
signiﬁcantly reduced AYP-induced scratching behavior
(Figure 1c). In addition, pretreatment with the nonselective
opioid receptor antagonist naloxone, used as an antipruritic
control drug, also signiﬁcantly inhibited AYP-induced
response (Figure 1d).
AYP-induced scratching behavior is dependent on GRP-
expressing ﬁbers
We found PAR-4 to be expressed in ~ 32% of all mouse skin
mast cells and AYP (200 nmol/site) i.d. injection was able to
cause mast cell degranulation; however, AYP-induced itch
was not dependent on mast cell product release (Supple-
mentary results and Supplementary Figure S1 online). In
addition, we detected PAR-4 on skin sensory neurons as
PAR-4 immunoreactivity was colocalized with the neuronal
marker PGP 9.5 (Figures 2a and b). PAR-4 was also found in
the soma of 47% of mouse dorsal root ganglion (DRG)
neurons (247/525). Of those, 39% (95/247), 34% (85/247),
and 27% (67/247) were small-, medium-, and large-diameter
neurons, respectively. To investigate the phenotype of PAR-4-
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Figure 1. Intradermal injection of AYPGKF-NH2 (AYP) causes itch-like behavior. (a) Scratching behavior elicited by AYP (30–500 nmol per site), histamine
(200 nmol per site), or control peptide YAP (200–500 nmol per site). (b) Time-course proﬁle of scratching behavior induced by AYP (200 nmol per site) or
histamine (200 nmol per site). Effect of (c) the proteinase-activated receptor-4 (PAR-4) antagonist pepducin P4pal-10 (5 mg kg−1, i.p., 60 min) and (d) the opioid
receptor antagonist naloxone (1 mg kg−1, i.p., 30 min) on AYP (200 nmol per site)-induced scratching. Each column represents the mean of 6–8 animals,
and the vertical bars represent the SEM. Signiﬁcant differences (*Po0.05) were indicated, as compared with the (a, b) saline- or (c, d) vehicle-treated group.
(a) One-way analysis of variance (ANOVA) followed by Bonferroni's test. (b) Two-way ANOVA followed by Bonferroni’s test. (c, d) Student’s t-test.
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expressing neurons, we performed a double labeling for
PAR-4 and gastrin-releasing peptide (GRP), a marker of
pruriceptive neurons (Sun and Chen, 2007). Interestingly,
77% (191/247) of all PAR-4-positive cells were colocalized
with GRP, and 87% of the GRP-positive cells (184/212)
expressed PAR-4 (Figure 2c). The functional relevance of
GRP-containing neurons for PAR-4-mediated scratching
behavior was then investigated in animals pretreated with
the selective GRP receptor (GRPR) antagonist RC-3095. Of
relevance, scratching behavior was signiﬁcantly prevented by
RC-3095 administration (Figure 2d).
AYP stimulates TRP channel–expressing DRG neurons
To determine whether AYP has direct effects on primary
sensory neurons, we performed live-cell calcium imaging.
Interestingly, AYP (200 μM) evoked an increase in intracellular
calcium concentration ([Ca2+]i) in only 1.5% (170/11,273)
of the DRG neurons from wild-type mice (Figure 3). To
investigate whether PAR-4 was localized to TRP channel–
expressing DRG neurons, cells were challenged sequentially
with AYP (200 μM), the TRPA1 agonist allyl isothiocyanate
(AITC; 50 μM), and the TRPV1 agonist capsaicin (1 μM),
followed by KCl (50mM). Of all AYP-sensitive neurons,
54.2% (70/129) were responsive to both capsaicin and AITC
(Figure 3a), whereas 31% (40/129) and 11.6% (15/129) were
responsive to only capsaicin (Figure 3b) or AITC (Figure 3c),
respectively. Consequently, 96.9% (125/129) of the AYP-
sensitive neurons were sensitive to either capsaicin or AITC,
and 3.1% (4/129) of AYP-responsive neurons were insensitive
to these agonists.
We next examined the responses of DRG neurons from
TRPV1 (Trpv1−/−) or TRPA1 (Trpa1−/−) knockout mice to
AYP. Notably, the responses to AYP were eliminated in the
Trpv1−/− neurons in comparison with neurons from wild-type
animals (0/2,363 neurons; Po0.0001, Chi-squared test).
However, no reduction was observed in the percentage of
AYP-responsive neurons from Trpa1−/− mice (1.97%;
54/2,745 neurons) where the proportion of AYP-responsive
neurons was slightly higher than in wild-type neurons
(Po0.05, Chi-squared test). Notably, almost all AYP-sensi-
tive Trpa1−/− neurons (53/54) responded to capsaicin,
consistent with the ﬁndings in preparations from wild-type
mice (Figure 3d).
PAR-4-mediated scratching behavior requires TRP channel
activation and SP release
We investigated the functional involvement of TRP channels
in AYP-induced scratching behavior. TRPV1 and TRPA1 are
expressed in sensory afferents neurons and are involved in
itch transmission (Imamachi et al., 2009; Wilson et al., 2011).
The importance of these channels was assessed in animals
pretreated with either the selective TRPV1 (SB366791) or
TRPA1 (HC-030031) receptor antagonists. Results show that
both antagonists were able to alleviate AYP-induced scratch-
ing behavior by 61% and 55%, respectively (Figures 4a
and b). Similarly, itch was attenuated in AYP-treated Trpv1−/−
mice in comparison with their WT counterparts (Figure 4c). In
contrast, TRPA1 deletion appeared to increase the scratching
response evoked by AYP, although this was not statistically
signiﬁcant (Figure 4c).
Substance P (SP), a neuropeptide found in TRPV1- and
TRPA1-positive ﬁbers, mediates itch by activating NK1
receptors (Steinhoff et al., 2006; Tey and Yosipovitch,
2011). Accordingly, pretreatment with the selective NK1
receptor antagonist FK888 signiﬁcantly reduced the number
of AYP-induced scratching bouts (52% inhibition; Figure 4d).
DISCUSSION
In the present study, we provide evidence that PAR-4
mediates scratching behavior in mice by activating TRP
channels and possibly causing the release of GRP and SP. A
role for PAR-4 in itch was ﬁrst suggested by Tsujii and
collaborators (2008) who demonstrated that AYP elicits
scratching behavior in mice at the dose of 100 nmol/site.
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Figure 2. Scratching behavior elicited by AYPGKF-NH2 (AYP) is dependent on GRP-expressing neurons. (a) proteinase-activated receptor-4 (PAR-4)
immunoreactivity in dermal nerve ﬁbers. Scale bar, 10 μm. Colocalization of PAR-4 with (b) the neuronal marker protein gene product 9.5 (PGP 9.5) in mouse
skin sections or (c) the pruriceptive neuron marker gastrin-releasing peptide (GRP) in mouse DRG sections. Arrowheads: PAR-4+/GRP+. Arrows: PAR-4+/GRP− .
Scale bar, 50 μm. (d) Effect of the GRP receptor antagonist RC-3095 (5mg kg−1, s.c., 60 min) on AYP (200 nmol per site)-induced scratching behavior.
Each column represents the mean of 6 animals, and the vertical bars represent SEM. Signiﬁcant differences (*Po0.05) were indicated, as compared with the
vehicle-treated group. Student’s t-test. epi: epidermis.
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Figure 3. AYPGKF-NH2 (AYP) evoked increases in [Ca
2+]i in dorsal root ganglion (DRG) neurons from wild-type but not Trpv1
−/− mice. (a) Typical recordings
of AYP (200 μM) evoked increases in [Ca2+]i in wild-type DRG neurons that were sensitive to AITC and capsaicin, indicative of transient receptor potential
ankyrin-1 (TRPA1) and transient receptor potential vanilloid-1 (TRPV1) coexpression. (b) AYP (200 μM)-responsive DRG neuron that was also responsive
to only capsaicin. (c) AYP (200 μM)-responsive DRG neuron that was also responsive to only AITC. (d) Example of DRG neurons from Trpa1−/− mice that
responded to AYP and capsaicin.
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Figure 4. AYPGKF-NH2 (AYP)-induced itch-like behavior was dependent on transient receptor potential (TRP) activation and Substance P (SP) release. Effects
of (a) the transient receptor potential vanilloid-1 (TRPV1) antagonist SB366791 (0.5 mg kg−1, i.p., 30 min), (b) the transient receptor potential ankyrin-1 (TRPA1)
antagonist HC-030031 (30 mg kg−1, i.p., 30 min), or (d) the NK1 receptor antagonist FK888 (3 mg kg− 1, i.v., 15 min) on AYP (200 nmol per site)-elicited
scratching behavior. (c) Scratching behavior induced by AYP (200 nmol per site) in TRPV1 (Trpv1−/−) and TRPA1 (Trpa1−/−) knockout mice. Each column
represents the mean of six animals, and the vertical bars represent SEM. Signiﬁcant differences (*Po0.05) were indicated, as compared with (a, b, d) the vehicle-
treated group or (c) the wild-type (WT) mice group. (a, b, d) Student’s t-test. (c) One-way ANOVA followed by Bonferroni’s test.
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Curiously, in a study conducted by the same group in 2009,
AYP at the same dose, failed to cause a pruriceptive response
in mice (Tsujii et al., 2009). These discrepant results may be
owing to the use of different strains of mice of different ages in
these studies. Here, scratching behavior was elicited by AYP
injection in the nape of the neck, and it was inhibited by the
selective PAR-4 antagonist (conﬁrming AYP selectivity) and
by naloxone, a centrally acting opioid receptor antagonist
used to treat some clinical itch conditions (Phan et al., 2010).
Indeed, AYP-induced hindpaw scratching bouts had been
previously described in the same model (Akiyama et al.,
2009) and later conﬁrmed in the cheek model of itch
(Akiyama et al., 2010) and in the alloknesis model
(Akiyama et al., 2012).
Both human and rat mast cells can express PAR-4 (Han
et al., 2011; Russell et al., 2011), and mast cells are consi-
dered to be central in some itching conditions (Steinhoff et al.,
2006). However, the contribution of histamine to AYP-
induced itch is rather controversial, with evidence suggesting
this response to be dependent on (Tsujii et al., 2008) and
independent of (Akiyama et al., 2009; Tsuji et al., 2009) this
pathway. Here, we show that PAR-4 is also expressed on
mouse mast cells and that AYP has the ability to cause their
degranulation. However, we present evidence that AYP elicits
itch in a mast cell–independent manner, with neither mast
cells nor their mediators playing a role in this response. It is
important to highlight that the discrepancies observed
between our study and previous studies addressing the
contribution of histamine to AYP-induced itch may be
related to differences in mouse strain, gender and/or age,
and differences in AYP dose; in addition to the use of different
strategies to investigate histamine contribution to this
response.
We also present evidence that PAR-4 is expressed on
sensory neurons innervating the mouse skin, as conﬁrmed by
its colocalization with the neuronal marker PGP 9.5. PAR-4
was previously detected on the rat DRG neurons colocalized
with neuropeptides such as SP (Asfaha et al., 2007). Herein,
PAR-4 was found in the soma of small- to large-sized DRG
neurons. We found that 77% of all PAR-4-positive neurons
contain the pruriceptive marker GRP and 87% of all GRP-
positive cells also express PAR-4. GRP can be found in
peptidergic ﬁbers innervating the mouse skin (Tominaga et al.,
2009) and in small- to medium-sized DRG neurons, which
also express SP and TRPV1 (Sun and Chen, 2007). Although
still debatable (Bautista et al., 2014), GRP-dependent
pruriceptive pathway is composed of peptidergic C ﬁbers
containing GRP and by GRPR in the spinal cord. The genetic
deletion or antagonism of GRPR, as well as the depletion of
GRP-positive ﬁbers, was able to prevent pruritus in mice (Sun
and Chen, 2007; Sun et al., 2009). Corroborating these
ﬁndings, the systemic treatment with the selective GRPR
antagonist RC-3095 prevented AYP-induced scratching beha-
vior, suggesting that this response involves the release of
GRP. This compound is known for its ability to cross the
blood–brain barrier (BBB) (Andoh et al., 2011); thus, it is
possible that spinal cord–located GRPR contribute to AYP-
induced itch.
We hypothesized that AYP induces itch by activating
PAR-4 on skin pruriceptive ﬁbers with cellular bodies in the
DRG. Surprisingly, calcium imaging experiments showed that
AYP evokes calcium inﬂux in only ∼ 1.5% of the total
cultured DRG neurons (small to medium diameter), contrast-
ing with the broad expression pattern of PAR-4 in small- to
large-diameter neurons (47%). This discrepancy may be
owing to the different approaches used in this study—i.e.,
immunohistochemistry (ex vivo) versus calcium imaging (in-
vitro)—as protein expression does not always translate in to
functional responses. Of all AYP-responsive neurons, ∼31%
and ∼ 11% were, respectively, responsive to only the TRPV1
agonist or the TRPA1 agonist. In addition, ∼ 54% of the AYP-
sensitive neurons were sensitive to both compounds. Thus, of
all PAR-4-expressing DRG neurons, ∼85% express TRPV1,
∼61% express TRPA1, and ∼ 54% express both channels.
Next, we stimulated cultured Trpv1−/− and Trpa1−/− mouse
DRG neurons with AYP and found that AYP response is lost
in Trpv1−/− but not in Trpa1−/−-derived DRG neurons. The
absence of any AYP-responsive DRG neurons from Trpv1−/−
mice is surprising given that a small percentage of the AYP-
responsive neurons appeared to be sensitive to AITC but not
to capsaicin. However, in these experiments, wild-type
neurons were challenged with AITC before capsaicin, raising
the possibility that AITC either desensitized TRPV1 or masked
any subsequent response that may have been evoked by
capsaicin.
Current studies have reported both additional and contrary
roles for TRPV1 and TRPA1 channels in the response to
different pruritogens (Wilson et al., 2011; Fernandes et al.,
2013). We investigated the in vivo contribution of TRPV1 and
TRPA1 receptors to AYP-induced itch. Although TRPV1
deletion or antagonism (by SB366791) clearly diminished
this response, conﬂicting results were found when assessing
the role of TRPA1 in this model. Indeed, treatment with the
selective TRPA1 antagonist HC-030031 reduced PAR-4-
mediated itch. However, no reduction in scratching behavior
was observed in Trpa1−/− mice and the response appeared to
be augmented. It is possible that these different results are due
to compensatory mechanisms in Trpa1−/− mice. Interestingly,
although the sample sizes are small, the percentage of AYP-
responsive DRG neurons was slightly higher in preparations
from Trpa1−/− than from wild-type mice. Indeed, the
existence of compensatory mechanisms in TRPA1− /− mice
was previously suggested in a study by Petrus and collabora-
tors (2007). This study compared the hyperalgesic responses
of TRPA1− /− mice with those treated with a selective TRPA1
antagonist AP18. AP18-treated mice exhibited less CFA-
induced hyperalgesia than mice lacking TRPA1. The authors
attributed the compensatory changes in TRPA1− /− mice to
possible changes in TRPV4 but not TRPV1 expression in skin
cells and DRG, a hypothesis that remains unclear.
Although a central effect was suggested for SB366791
following its systemic administration (Fernandes et al., 2011),
to our knowledge, no studies have investigated the ability of
HC-030031 to cross the blood–brain barrier when systemi-
cally administered. However, it is possible that based on the
pharmacologic properties of HC-030031 (see the PubChem
ES Patricio et al.
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Public Chemical Database) this compound may be able to
penetrate the BBB, although the extent to which this happens
is not completely known at this time. Thus, these drugs may
be acting at both central and peripheral levels in order to
inhibit AYP-induced itch. Indeed, in addition to afferent
sensory ﬁbers, TRPV1 and TRPA1 are also expressed on skin
mast cells and keratinocytes (Biro and Kovacs, 2009; Buch
et al., 2013; Oh et al., 2013). Although a neuronal role has
been proposed for TRP channels in itch, non-neuronal TRPA1
was recently implicated in this phenomenon (Fernandes et al.,
2013). Thus, we can suggest that TRPV1/TRPA1-expressing
pruriceptive ﬁbers, as well as skin non-neuronal cells,
mediate AYP-induced scratching behavior.
SP is a neuropeptide present in TRPV1/TRPA1-expressing
sensory neurons, and it has been implicated in itch
transmission through its NK1 receptor at both peripheral
and spinal sites (Andoh et al., 1998; Akiyama et al., 2010).
Here, we show that AYP-induced itch is reduced by NK1
receptor antagonism (by FK888), suggesting that SP is released
upon sensitization/activation of TRP channels by the PAR-4
agonist. Indeed, SP was found to be expressed on pruriceptive
neurons together with TRPV1 or TRPA1 channels (Sun and
Chen, 2007; Imamachi et al., 2009; Liu et al., 2009; Wilson
et al., 2013). SP release may occur at both peripheral and
central levels, as TRPV1 activation can cause its release at
both sites and FK888 was suggested to cross the BBB (Rudd
et al., 1999; Willcockson et al., 2010; Steagall et al., 2012).
Taken together, our ﬁndings suggest that itch-like behavior
induced by PAR-4 agonist is dependent on the action of AYP
on skin sensory neurons and perhaps on non-neuronal cells.
In turn, this may trigger the activation of TRPV1 and TRPA1
channels, as well as the possible release of SP and GRP,
transmitting the pruriceptive signal to the CNS. Overall, our
data suggest that PAR-4-selective antagonists can constitute
interesting tools for the attenuation of chronic itch, which
remains a challenge to treat in the clinical practice. However,
future studies addressing the intracellular pathways connect-
ing the activation of PAR-4 and TRPV1/TRPA1 sensitization
are of importance to further understand the pathophysiology
of itch, and remain to be investigated.
MATERIALS AND METHODS
Animals
Female adult CD1 mice (8–10 weeks old) from the Universidade
Federal de Santa Catarina were used. In addition, female mice
(8–12 weeks old) either WT C57BL/6/J, TRPV1-knockout (Trpv1−/−;
C57BL/6 background (Costa et al., 2008)), or TRPA1-knockout
(Trpa1−/−; C57BL/6 J background (Andersson et al., 2013)) were
used. Mice were kept in a climatically controlled environment
with ad libitum access to food and water and were acclimatized
in the procedure room for 1 hour before the experiments.
Experimental procedures were approved by the local ethics
committee of the Universidade Federal de Santa Catarina and King
´s College London, and were performed in accordance with the
National Institutes of Health Animal Care Guidelines (NIH
publications nº.80-23) and the UK Home Ofﬁce Animals (Scientiﬁc
Procedures) Act of 1986.
Scratching behavior
The experiments were performed as previously described (Costa
et al., 2010). Mice received a dorsal i.d. injection of either vehicle
(saline; 50 μl per site), AYP (30–500 nmol per site), YAP (200 or
500 nmol per site), or histamine (200 nmol per site). Scratching
behavior was observed for either 30 or 60minutes, and quantiﬁed as
the number of scratches made with the mouse hindpaws near the
injected site. The results are expressed as the number of scratches in
30minutes or in intervals of 10minutes.
Immunohistochemistry analysis
PAR-4 expression in the mouse skin and on DRG neurons was
assessed by immunoﬂuorescence staining followed by confocal
microscopy. Anesthetized animals were perfused with saline
followed by 4% PFA phosphate buffer. Mouse rostral back skin
samples (~1.5 cm2) and DRGs from cervical and thoracic regions
were collected. Skin samples were embedded in parafﬁn and
sectioned (4 μm). DRG samples were ﬁxed in 4% PFA, cryopreserved
in 30% sucrose, embedded in Tissue-Tek (Sakura Finetek, Torrance,
CA), and sectioned (16 μm) at − 15 °C on a cryostat (Leica,
Heidelberg, Germany). Slices were incubated overnight at 4 °C with
PAR-4 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), protein
gene product 9.5 (PGP 9.5) (1:100; Santa Cruz Biotechnology), or
GRP (1:1000; Immunostar, Hudson, WI) antibodies, followed by
incubation with secondary antibodies conjugated to Alexa Fluor-568
(1:750) or Alexa Fluor-488 (1:400) (Molecular Probes, Invitrogen,
New York, NY) at room temperature for 3 h. A series of images from
different focal planes within the DRG section were collected into a
single ﬁle (e.g., z-series), using confocal microscopy (Leica). In DRG
slices, the number of PAR-4+, GRP+, or PAR-4+/GRP+ neurons was
determined with the NIH ImageJ 1.36b imaging software (NIH,
Bethesda, MD). Images from three random ﬁelds per section of skin
samples were evaluated and captured as described above.
Cell culture and intracellular [Ca2+] measurements
DRG neurons were obtained and prepared from adult WT, Trpv1−/−,
or Trpa1−/− female C57BL6/J mice, as previously described (Bevan
and Winter, 1995; Andersson et al., 2012). Isolated neurons were
cultured in MEM supplemented with 10% fetal bovine serum,
100 Uml− 1 penicillin, 100 μgml−1 streptomycin, 2 mM L-glutamine,
and 50 ngml− 1 NGF (Promega, Southampton, UK) for less than
24 hours before experimentation.
Cultured DRG neurons were loaded with 2.5 μM Fura-2 AM
(Molecular Probes, Paisley, UK) in the presence of 1 mM probenecid
for ∼ 1 hour. The dye loading and subsequent experiments were
performed in a saline solution (pH 7.4) containing (in mM) 140 NaCl,
5 KCl, 10 glucose, 10 HEPES, 2 CaCl2, and 1 MgCl2. AYP (200 μM)
was applied to cells by local continuous microperfusion of this
solution through a ﬁne tube placed very close to the cells being
studied. TRP channel expression in individual neurons was tested
functionally by sequential application of the agonists for TRPV1
(capsaicin, 1 μM; Sigma-Aldrich, UK) and TRPA1 (allyl isothiocyanate
(AITC), 50 μM; Sigma-Aldrich, UK). All neurons were ﬁnally identiﬁed
by the increase in intracellular calcium concentration evoked by
depolarization with 50mM KCl. Experiments were conducted at
35 °C. Images of a group of cells were captured every 1–2 seconds
using 340- and 380-nm excitation wavelengths with emission
measured at 4510 nm with a microscope-based imaging system
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(PTI, New Jersey, NJ). Analyses of emission intensity ratios at 340 nm/
380 nm excitation (R, in individual cells) were performed using the
Image Master suite of software.
Drugs
AYPGKF-NH2 (AYP), YAPGKF-NH2 (YAP), and N-palmitoyl-SGRRY-
GHALR-NH2 (P4pal-10; GenScript, Piscataway, NJ,); naloxone
(Research Biochemicals International, Natick, MA); histamine, RC-
-3095, and SB366791(Sigma-Aldrich, St Louis, MO); FK888 (donated
by the Fujisawa Pharmaceutical, Osaka, Japan); and HC-030031
(synthesized at the Universidade Federal de Santa Catarina, as
previously described (Moram et al., 2007)) were used. All drugs were
dissolved in saline, except HC-030031 and FK888. HC-030031 stock
solution (10−1 M) was prepared in saline with 90% dimethylsulfoxide
and 10% Tween 80. FK888 stock solution (10−3 M) was prepared in
saline containing 5% ethanol. For in vivo experiments, the ﬁnal
concentrations of dimethylsulfoxide and ethanol did not exceed
5% and 1%, respectively.
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